Metastatic Castration-resistant Prostate Cancer Clinical Trials

343 clinical trials for Metastatic Castration-resistant Prostate Cancer across international registries, including 86 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer — RECRUITING · PHASE2
• A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. — RECRUITING · PHASE3
• Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) — RECRUITING · PHASE1
• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) — RECRUITING · PHASE2
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) — RECRUITING · PHASE3
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer — RECRUITING · PHASE3
• Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE1
• Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE1
• A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer — RECRUITING · PHASE1
• Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer — RECRUITING · PHASE1
• Cannabidiol for Pain Relief of Patients With End-stage mCRPC — RECRUITING · PHASE2
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors — RECRUITING · PHASE1
• A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE2
• REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma — RECRUITING · PHASE1
• A Study in Patients With Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE1
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer — RECRUITING · PHASE2
• Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma — RECRUITING · PHASE1
• Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer — RECRUITING · PHASE1
• A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) — RECRUITING · PHASE3
• FOG-001 in Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer — RECRUITING · PHASE3
• The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) — RECRUITING · PHASE3
• A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer — RECRUITING · PHASE3
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas — RECRUITING · PHASE1
• Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed) — RECRUITING
• A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer — RECRUITING · PHASE1
• Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer — RECRUITING
• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors — RECRUITING · PHASE1
• A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) — RECRUITING · PHASE1
• Post Marketing Study on Pluvicto in Korea — RECRUITING
• AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) — RECRUITING · PHASE3
• Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC — RECRUITING · PHASE2
• Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — RECRUITING · PHASE2
• XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE2
• A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE2
• The COSMYC Trial (COmbined Suppression of MYC) — RECRUITING · PHASE2
• Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer — RECRUITING · PHASE1
• AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) — RECRUITING · PHASE1
• Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T — RECRUITING · PHASE1
• PRostate Olaparib Real World Evidence Study — RECRUITING
• Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer — RECRUITING · PHASE2
• A Phase I Trial of A-CAR032 in Participants With mCRPC — RECRUITING · PHASE1
• Study With [225Ac]Ac-FL-020 in mCRPC Participants — RECRUITING · PHASE1
• A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer — RECRUITING · PHASE1
• A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) — RECRUITING · PHASE2
• A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) — RECRUITING · PHASE1
• Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC — RECRUITING · PHASE2
• Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer — RECRUITING
• Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection — RECRUITING · PHASE1

Refine this search